Skip to content
PeptideFactSheets

Flavonoid and experimental senolytic · Fact sheet

Fisetin

Also known as senolytic flavonoid · dietary fisetin

Fisetin is not an FDA-approved senolytic or anti-aging drug. Animal studies and early human mechanistic research justify clinical trials, but there is no proof that fisetin extends human life, reverses frailty, or prevents age-related disease.

In clinical trialsMostly animal or lab research
Aging & energy

What is Fisetin?

Fisetin is a flavonoid found in small amounts in foods such as strawberries and apples.

In geroscience it is studied as a senolytic—a compound intended to preferentially remove some senescent cells—but cell type, exposure, and model strongly affect that claim.

Benefits people look for

A prominent mouse study reported reduced senescence markers, improved health measures, and longer lifespan.

Human trials now examine vascular function, frailty, and treatment-related physical decline, but a trial design or biomarker shift is not a clinical benefit.

What the evidence supports

  • Preclinical work supports a senolytic hypothesis and identified cell-type-specific effects.
  • Early human research may clarify target engagement, but meaningful clinical outcomes remain unproven.
All research areas
  • Cellular senescence
  • Frailty
  • Vascular function
  • Physical function after cancer treatment

Anecdotal reports & lived experiences

Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens.

No attributable personal reports are summarized here yet. The benefits above describe research interests; the side effects below come from the cited medical sources.

We do not fill this gap with unsourced testimonials or estimated success rates.

Side effects & risks

  • A food constituent is not automatically safe at concentrated research exposure.
  • Human adverse-event data are too limited to define uncommon, interaction, or long-term risks.
  • Supplement identity, purity, and formulation may not match clinical-trial material.

This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.

Clinical research: how strong is it?

Mostly animal or lab research

The most influential healthspan and lifespan findings are from mice and cell systems. Human work is early, mechanistic, small, or still recruiting and does not establish better function, fewer diseases, or longer life.

Selected research to read

FDA approval & research status

Fisetin is being studied in human trials but has no FDA-approved drug use for senescence, frailty, cardiovascular aging, cancer recovery, or longevity. Supplement products are not FDA approved for effectiveness.

No FDA-approved use is documented in the records summarized on this page.

Small human senolytic trials

Fisetin has a small Phase 2 frailty trial record and early human mechanistic research, but no FDA-approved senolytic, frailty, or longevity indication.

This summarizes the cited product or research record. Trial phases do not establish successful completion of earlier stages, and a stopped program is not ongoing development. Approval applies only to the labeled product, use and population.

What we still don’t know

  • Whether fisetin reliably clears clinically relevant senescent cells in people
  • Whether biomarker effects improve function, disease risk, or survival
  • Which tissues and populations could benefit or be harmed
  • Long-term safety and interactions

The takeaway

Fisetin is one of the better-known experimental senolytics, but its reputation still rests mainly on preclinical work. Human longevity benefit has not been shown.

Sources & further reading

Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.

  1. 1
    pubmedPreclinical fisetin healthspan and lifespan study

    Cell, tissue, and mouse evidence that motivated human senolytic research.

  2. 2
    clinical trialsClinicalTrials.gov: AFFIRM-LITE

    Small Phase 2 frailty trial record with no public outcomes result.

  3. 3
    pubmedEarly human fisetin vascular-aging study

    Mechanistic human study that does not establish longevity or disease prevention.

  4. 4
    fdaFDA: dietary supplements are not preapproved for effectiveness

    FDA explanation of the regulatory distinction between approved drugs and marketed dietary supplements.

How we assess sources · Suggest a correction